ario pharma

Ario Pharma Ltd is developing new therapeutics for the treatment of respiratory indications.

The Company is currently evaluating the anti-tussive properties of its lead asset XEN-D0501, a best-in-class oral TRPV1 inhibitor, with Phase 2 clinical trials currently ongoing for chronic idiopathic cough (CIC) and COPD cough.

A TRPA1 lead optimisation project is also underway, focusing on asthma.

Find out more

Please contact us to arrange a meeting at one of the events we are attending.

latest news

Ario Pharma Acquires PharmEste’s TRPA1 Research Assets

more news from ario pharma